Comparison of cell line and patient sample data identified new candidate drugs for CML BC, such as vascular endothelial growth factor receptor and nicotinamide phosphoribosyltransferase inhibitors. Here, NAMPT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.